News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News Novartis to buy ophthalmology firm Encore Vision Swiss pharma buys treatment for common age-related vision problem.
News Novartis/Ophthotech eye combo fails in phase 3 Lucentis and pegpleranib combination misses goal in wet AMD.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
